GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0030239 | Oral cavity | NEOLP | myofibril assembly | 15/2005 | 63/18723 | 2.23e-03 | 1.45e-02 | 15 |
GO:00487383 | Oral cavity | NEOLP | cardiac muscle tissue development | 40/2005 | 236/18723 | 2.26e-03 | 1.47e-02 | 40 |
GO:003367423 | Oral cavity | NEOLP | positive regulation of kinase activity | 70/2005 | 467/18723 | 2.33e-03 | 1.50e-02 | 70 |
GO:001491012 | Oral cavity | NEOLP | regulation of smooth muscle cell migration | 19/2005 | 89/18723 | 2.46e-03 | 1.56e-02 | 19 |
GO:003440521 | Oral cavity | NEOLP | response to fluid shear stress | 10/2005 | 35/18723 | 2.88e-03 | 1.77e-02 | 10 |
GO:001490913 | Oral cavity | NEOLP | smooth muscle cell migration | 20/2005 | 97/18723 | 2.95e-03 | 1.81e-02 | 20 |
GO:006054114 | Oral cavity | NEOLP | respiratory system development | 35/2005 | 203/18723 | 3.08e-03 | 1.88e-02 | 35 |
GO:005500111 | Oral cavity | NEOLP | muscle cell development | 32/2005 | 184/18723 | 3.95e-03 | 2.26e-02 | 32 |
GO:003032416 | Oral cavity | NEOLP | lung development | 31/2005 | 177/18723 | 4.04e-03 | 2.30e-02 | 31 |
GO:004814531 | Oral cavity | NEOLP | regulation of fibroblast proliferation | 17/2005 | 80/18723 | 4.25e-03 | 2.40e-02 | 17 |
GO:004341013 | Oral cavity | NEOLP | positive regulation of MAPK cascade | 70/2005 | 480/18723 | 4.59e-03 | 2.56e-02 | 70 |
GO:004814431 | Oral cavity | NEOLP | fibroblast proliferation | 17/2005 | 81/18723 | 4.85e-03 | 2.64e-02 | 17 |
GO:00720017 | Oral cavity | NEOLP | renal system development | 47/2005 | 302/18723 | 5.60e-03 | 2.97e-02 | 47 |
GO:00434053 | Oral cavity | NEOLP | regulation of MAP kinase activity | 30/2005 | 177/18723 | 7.45e-03 | 3.73e-02 | 30 |
GO:003526511 | Oral cavity | NEOLP | organ growth | 30/2005 | 178/18723 | 8.07e-03 | 3.98e-02 | 30 |
GO:00018226 | Oral cavity | NEOLP | kidney development | 45/2005 | 293/18723 | 8.36e-03 | 4.08e-02 | 45 |
GO:00109598 | Oral cavity | NEOLP | regulation of metal ion transport | 59/2005 | 406/18723 | 9.36e-03 | 4.44e-02 | 59 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0451019 | Oral cavity | OSCC | Focal adhesion | 128/3704 | 203/8465 | 1.71e-08 | 1.63e-07 | 8.31e-08 | 128 |
hsa0521510 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0523016 | Oral cavity | OSCC | Central carbon metabolism in cancer | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa0481026 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0401518 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa04510110 | Oral cavity | OSCC | Focal adhesion | 128/3704 | 203/8465 | 1.71e-08 | 1.63e-07 | 8.31e-08 | 128 |
hsa0521515 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0523017 | Oral cavity | OSCC | Central carbon metabolism in cancer | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0401519 | Oral cavity | OSCC | Rap1 signaling pathway | 107/3704 | 210/8465 | 2.01e-02 | 4.34e-02 | 2.21e-02 | 107 |
hsa0451026 | Oral cavity | EOLP | Focal adhesion | 60/1218 | 203/8465 | 1.42e-08 | 1.83e-07 | 1.08e-07 | 60 |
hsa0516541 | Oral cavity | EOLP | Human papillomavirus infection | 79/1218 | 331/8465 | 1.96e-06 | 1.63e-05 | 9.60e-06 | 79 |
hsa0521524 | Oral cavity | EOLP | Prostate cancer | 31/1218 | 97/8465 | 7.90e-06 | 4.73e-05 | 2.79e-05 | 31 |
hsa0152124 | Oral cavity | EOLP | EGFR tyrosine kinase inhibitor resistance | 25/1218 | 79/8465 | 7.03e-05 | 3.25e-04 | 1.91e-04 | 25 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDGFRB | SNV | Missense_Mutation | rs756509220 | c.1339N>G | p.Ile447Val | p.I447V | P09619 | protein_coding | tolerated(0.21) | benign(0) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDGFRB | SNV | Missense_Mutation | novel | c.2668N>T | p.Gly890Trp | p.G890W | P09619 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
PDGFRB | SNV | Missense_Mutation | rs757668250 | c.751N>T | p.Arg251Cys | p.R251C | P09619 | protein_coding | deleterious(0.04) | probably_damaging(0.982) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
PDGFRB | SNV | Missense_Mutation | rs751904503 | c.2326N>A | p.Asp776Asn | p.D776N | P09619 | protein_coding | deleterious(0.01) | possibly_damaging(0.738) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PDGFRB | SNV | Missense_Mutation | | c.1310N>A | p.Arg437His | p.R437H | P09619 | protein_coding | tolerated(0.47) | possibly_damaging(0.769) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PDGFRB | SNV | Missense_Mutation | novel | c.871T>C | p.Cys291Arg | p.C291R | P09619 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A201-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PDGFRB | SNV | Missense_Mutation | novel | c.3211G>A | p.Glu1071Lys | p.E1071K | P09619 | protein_coding | deleterious(0.03) | benign(0.091) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PDGFRB | SNV | Missense_Mutation | novel | c.1359C>A | p.Asp453Glu | p.D453E | P09619 | protein_coding | deleterious(0.01) | benign(0.4) | TCGA-E2-A1B5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PDGFRB | SNV | Missense_Mutation | | c.1858N>T | p.His620Tyr | p.H620Y | P09619 | protein_coding | tolerated(1) | benign(0.194) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PDGFRB | insertion | Nonsense_Mutation | novel | c.725_726insTTTTTAAGATGGAGTCTGGCTCTGTTGCCCAGGCTGGAGTGCA | p.Val243PhefsTer2 | p.V243Ffs*2 | P09619 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | CHEMBL576982 | QUIZARTINIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | PAZOPANIB | PAZOPANIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | | SOTRASTAURIN | SOTRASTAURIN | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | | SORAFENIB | SORAFENIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | | Imatinib | IMATINIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | | PMID25656651-Compound-21a | | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | 249565577 | FAMITINIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | CHEMBL2105728 | CRENOLANIB | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | 385612234 | | |
5159 | PDGFRB | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE | inhibitor | CEDIRANIB | CEDIRANIB | |